亞盛醫藥-B(06855.HK)於63屆美國血液學會年會公佈三個在研新藥(奧雷巴替尼、APG-2575、APG-1252)六項研究最新研究進展
格隆匯12月14日丨亞盛醫藥-B(06855.HK)公吿，公司在第63屆美國血液學會(American Society of Hematology，ASH)年會已公佈三個在研新藥(奧雷巴替尼、APG-2575、APG-1252)的六項研究進展。北京大學人民醫院血液科黃曉軍教授和江倩教授是原創1類新藥耐立克®(奧雷巴替尼片)相關研究的主要研究者，其中一項研究由江倩教授在會議期間作口頭報吿。耐立克®相關臨牀研究已連續四年入選ASH年會口頭報吿，充分顯示了國際血液學界對其療效和安全性的認可。
每年一度的ASH年會是全球血液學領域規模最大、涵蓋最全面的國際學術盛會之一，匯聚該領域最新、最前沿的研發進展。今年，亞盛醫藥共有三個原創新藥(耐立克®、APG-2575、APG-1252)的六項研究進展在本屆ASH年會上獲得展示。
其中，耐立克®為亞盛醫藥原創1類新藥，剛剛於今年11月獲得中國上市批准，用於治療酪氨酸激酶抑制劑(TKI)耐藥，並伴有T315I突變的慢性髓細胞白血病(CML)慢性期(CP)或加速期(AP)的成年患者，是國內首個獲批上市的第三代BCR-ABL靶向耐藥CML治療藥物。
此外，公司細胞凋亡品種在研原創1類新藥Bcl-2選擇性抑制劑lisaftoclax(APG-2575)和Bcl-2/Bcl-xL雙靶點抑制劑pelcitoclax(APG-1252)以壁報展示形式，分別公佈了兩項臨牀數據和一項臨牀前研究結果。
值得關注的是，APG-2575治療血液腫瘤的多中心、開放標籤I期單藥研究的數據顯示，APG-2575具有良好的耐受性，無任何腫瘤溶解綜合症(TLS)發生。截止數據分析截點(2021年7月27日)，在25例至少完成了一次腫瘤評估的患者中(共入組31例)，有9例獲得了完全緩解(CR)或部分緩解(PR)。接受200mg及以上劑量治療的6例慢性淋巴細胞白血病(CLL)受試者均獲益，為1例CR和5例PR。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
